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ical trials registries, and EMA reports. We extracted data for depression severity
(mean differences or related statistics) on the primary comparisons of 1) agomela-
tine 25 mg/day versus placebo, and 2) agomelatine 25 mg/day versus any SSRI. We
calculated Hedges’ g effect size for each trial and combined them by the inverse
variance method assuming a random effects model. Two meta-analyses were con-
ducted: one with the results of published and unpublished trials and the other only
with results of published trials. RESULTS: Ten trials (5 unpublished) gave data on
the efficacy of agomelatine versus placebo. Overall, the results were homogeneous
(I2  9.2%), and showed agomelatine was better than placebo for reducing the
severity of depression at 8 weeks (g  -0.18; 95% CI  -0.25 to -0.10; p 0.0001).
However when the analysis was restricted to published trials the effect size was
45% overestimated (g  -0.26; 95% CI  -0.36 to-0.15; p  0.0001; I2  3.4%). 7 trials
(4 unpublished) gave data on the comparison of agomelatine versus any SSRI.
There was no difference in efficacy with all trials combined (g 0.01; 95% CI -0.16
to 0.18; p 0.87), but agomelatine significantly outperformed SSRIs in the subset of
published trials (g  -0.17; 95% CI  -0.29 to -0.05; p  0.0052). CONCLUSIONS:
When combining all available data agomelatine presents a small to moderate effi-
cacy as antidepressant with similar effect sizes to those reported for SSRIs. Previ-
ous reports pointing to better results of agomelatine as compared with SSRIs are
the result of selective publication bias.
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OBJECTIVES: This study aimed to describe the functional level of patients treated
with olanzapine long-acting injection (OLZ-LAI) during maintenance treatment of
schizophrenia for up to 24 weeks. A secondary objective was to compare OLZ-LAI
with oral olanzapine on these functional measures. METHODS: We present a sec-
ondary analysis of a multicenter, randomized, double-blind, study comparing the
safety and efficacy of OLZ-LAI (405mg/4weeks, 300mg/2weeks, 150 mgs/2weeks,
active depot groups) with oral olanzapine and OLZ-LAI 45mg/4weeks (very low
dose/pseudo-placebo group) for maintenance treatment of clinically stable pa-
tients with schizophrenia (n1064). Heinrichs and Carpenter’s Quality of Life Scale
(QLS) mean total scores were calculated for each of the three active OLZ-LAI treat-
ment groups and for their pooled group. Patients’ functional status was also clas-
sified - at baseline and endpoint, per QLS - as “good,” “moderate” or “poor” using a
recent data-driven approach to defining levels of functioning in schizophrenia.
RESULTS: Over the 24-week treatment period, the OLZ-LAI-treated patients im-
proved their level of functioning - per QLS total score - from a mean (SD) of 66.4
(18.9) to 72.0(19.1) (p0.001). At baseline, 16.8% of the OLZ-LAI-treated patients
were identified as having a “good” level of functioning, which increased to 27.5%
following up to 24 weeks of therapy (p0.001). There was a decrease both in the
proportion of patients with a “moderate” level of functioning (from 66.8 to 61.8%;
p0.002) and patients with a “poor” level of functioning (from 16.3% to 10.7%;
p0.06). Results were not significantly different between oral olanzapine and the
three OLZ-LAI active dosing groups or the pooled OLZ-LAI treatment group.
CONCLUSIONS: In this 24-week study, clinically stable patients treated with OLZ-
LAI maintained their favorable baseline level of functioning or further improved it
over time. Results did not significantly differ between OLZ-LAI and oral olanzapine.
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OBJECTIVES: Data on attaining and maintaining symptom remission associated
with specific antipsychotic medications are rare and variant. The aim of this study
is to examine remission rates and their variation by antipsychotic medication in
chronic schizophrenia in the National Institute of Mental Health Clinical Antipsy-
chotic Trials of Intervention Effectiveness (CATIE) give it has an 18-month duration
and representative antipsychotic medications. METHODS: Symptom remission
was examined using the Remission in Schizophrenia Working Group remission
criteria of attaining and maintaining for 6 months with mild ratings on 8 specific
Positive and Negative Syndrome Scale (PANSS) items. Remission rates were as-
sessed (a) up to 18 months across CATIE’s switching phases (n1332); and (b) in
phase 1 (that involved double-blind randomization to one of five antipsychotic
medications) to compare antipsychotic medication differences in attaining and
maintaining remission among patients not in remission at baseline (n941).
RESULTS: A total of 15.7% of patients were in symptomatic remission at baseline.
Across the switching phases of CATIE only 11% attained and then maintained at
least 6 months of symptomatic remission, and 55.5% (n623) experienced no
symptom remission at any visit. In phase 1, attaining and maintaining remission
for 6 months was highest for the olanzapine (13.3%) medication group followed by
quetiapine (8.9%), ziprasidone (6.6%), perphenazine (6.2%), and risperidone (6.2%)
groups. CONCLUSIONS: As currently defined, remission appears to be a very diffi-
cult therapeutic target to attain and maintain in chronic schizophrenia and may
differ by antipsychotic medication. Pragmatically, remission gradients may be ef-
fectively studied by applying modified duration and symptom criteria.
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OBJECTIVES:Despite marked heterogeneity among patients with schizophrenia in
their level of functioning, little is known what “good” “moderate” or “poor” levels of
functioning look like on various functional measures. This study used an empirical
approach to identify and then validate these functional definitions.METHODS:We
used baseline data of a multicenter, effectiveness study comparing antipsychotics
in the treatment of outpatients with schizophrenia (n524; NCT00320489), as this
study included several functional measures. A cluster analysis used the Heinrich’s
Carpenter Quality of Life Scale (QLS), the 12-item Short Form Health Survey (SF-12)
mental composite score, and a previously studied productivity measure, to classify
patients into functional groups. A three cluster solution was chosen to maximize
simplicity, explanatory power and separation among the groups. Clusters were
validated using two other functional measures and two previously published def-
initions of functional levels: an empirical definition that incorporated functioning
and symptom severity, and another, using theoretically-driven definitions. Classi-
fication and regression tree (CART) analysis was used to establish the criteria for
classifying functioning as “good” “moderate” or “poor” with the QLS. RESULTS: The
three clusters consistently differentiated patients on the QLS, SF-12 and produc-
tivity measures, reflecting “good” “moderate” and “poor” functional levels. The
clusters similarly differed on other functional measures (the Schizophrenia Out-
comes Functioning Interview [SOFI] and the Euro-QOL-5D scale), and were concor-
dant with two previously published functional classifications. The CART analysis
identified “good” functioning as QLS total score 84.5, whereas “moderate” and
“poor” functioning were separated by a cut-off score of 15.5 on the QLS intrapsychic
foundation domain. Sensitivity ranged from 86% to 93% and specificity from 89% to
99%. CONCLUSIONS: The substantial heterogeneity among schizophrenia patients
in their level of functioning can be reliably classified in an empirical manner, using
specific cut-off scores on commonly used functional measures. Findings have util-
ity for schizophrenia research.
PMH6
EFFECTIVENESS OF LONG-ACTING INJECTABLE RISPERIDONE AND ORAL
ATYPICAL ANTIPSYCHOTICS IN A 24-MONTHS OBSERVATIONAL STUDY IN
ADULT PATIENTS WITH SCHIZOPHRENIA IN GERMANY
Hargarter L1, Fleischmann J2, Diels J3, Rabinowitz J4, Hemels M5, Gaudig M2,
Van sanden S3, Schreiner A6
1Medical Affairs, Janssen Germany, Neuss, Germany, 2Health Economics, Janssen Germany,
Neuss, Germany, 3EMEA HEMAR Analytics, Janssen EMEA, Beerse, Belgium, 4Bar Ilan
University, Ramat Gan, Israel, 5EMEA Hemar Analytics, Janssen EMEA, Birkerod, Denmark,
6Medical Affairs, Janssen EMEA, Neuss, Germany
OBJECTIVES: Treatment continuity plays a major role in achieving favorable out-
comes in patients suffering from schizophrenia. Long-acting injectable risperidone
(RLAI) has shown its beneficial effects compared to oral antipsychotics (oAP) in
randomized controlled trials, but observational data reflecting routine clinical
practice are sparse. Objective is to evaluate the clinical effectiveness of RLAI com-
pared to oAP in clinical practice. METHODS: A total of 746 patients with schizo-
phrenia newly initiated from oral antipsychotic treatment to either an atypical oAP
(n268) or RLAI (n478) were enrolled in this prospective, longitudinal 24-month
open-label observational study. Primary efficacy measure was time to discontinu-
ation of medication using Kaplan-Meier and multivariate Cox proportional hazards
regression, adjusting for patient demographics, disease severity and treatment
history. RESULTS: At baseline, patients treated with RLAI were more likely to be
male, non-compliant, substance abuser, and had significantly higher levels of psy-
chotic symptoms and disease severity, poorer psychosocial functioning (GAF, days
unable to work), and poorer cognitive function, compared to patients treated with
oral antipsychotics. 107 patients were identified as having a history of poor adher-
ence (RLAI: n84; oral: n23) with previous antipsychotic treatment. Time to treat-
ment discontinuation was numerically but not significantly longer for patients
treated with RLAI compared to patients treated with atypical oAP. Among the
subset of patients with history of poor adherence this difference was significant
(unadjusted hazard ratio0.42, p.014; adjusted hazard ratio0,35; p0,0098).
Symptom improvement was significantly better for patients on RLAI as compared
to oAP on the Positive and Negative Syndrome Scale (PANSS) total score (p.029),
positive (p.004) and negative (p.023) subscores, respectively. CONCLUSIONS: In
routine clinical practice, RLAI appears to be used more frequently in patients with
more severe schizophrenia, substance abuse and poor adherence. The benefits of
RLAI treatment compared to oAP seem to be most pronounced in a subset of pa-
tients with poor adherence.
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OBJECTIVES: Asenapine is a novel antipsychotic indicated for the treatment of
moderate to severe manic episodes associated with bipolar I disorder. The clinical
programme included one 12-week trial versus olanzapine in monotherapy and one
12-week adjunct therapy trial versus placebo. While no head-to-head data were
available to compare asenapine with all atypical antipsychotics, the objective of
this project was to provide comparative efficacy data of asenapine versus olanzap-
ine, quetiapine and aripiprazole in both monotherapy and adjunct therapy using
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indirect comparison techniques. METHODS: All twelve-week randomised con-
trolled trials of olanzapine, quetiapine and aripiprazole conducted in monotherapy
or in adjunct therapy were identified through a literature review. Five mono-
therapy studies were found, allowing the comparison of asenapine versus quetia-
pine and aripiprazole, with olanzapine and haloperidol as common references,
using Bucher’s method (Bucher et al., J Clin Epidemiol 1997). One twelve-week and
four six-week placebo-controlled adjunctive therapy trials were identified, en-
abling the comparison of asenapine to olanzapine, quetiapine and aripiprazole
through pairwise comparisons using placebo as a common reference. The out-
comes used for comparison were the Young Mania Rating Scale (YMRS) change
from baseline, YMRS response and remission rates. RESULTS: In monotherapy,
the differences of mean YMRS change from baseline to week 12 between
asenapine versus quetiapine and aripiprazole were 0.10 (p0.959) and 1.76
(p0.342), respectively. Relative risks for response and remission were close to
one. In adjunct therapy, the differences of mean YMRS change from baseline to
week 6 between asenapine versus olanzapine, quetiapine and aripiprazole were
0.63 (p0.656), 0.10 (p0.967) and -0.10 (p0.946), respectively. Relative risks for
response and remission were numerically in favour of asenapine but not statis-
tically significant. CONCLUSIONS: The results of these indirect comparisons con-
sistently showed comparable efficacy of asenapine versus the investigated atypical
antipsychotics.
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OBJECTIVES: Reducing hospital readmission rates has emerged as an important
strategy for increasing the quality of health care, while reducing the cost of care. An
analysis was conducted using an US government-funded tool to investigate the
impact of post-hospitalization follow-up on readmissions for depression.
METHODS: Public (Medicare) and proprietary (MarketScan Commercial, Medicare
Supplemental and Medicaid) administrative databases were standardized and
linked via a common data model. A web-based tool was developed that captured
the logic typically required by CER methods, e.g. searches on drugs, diagnoses, and
procedures, application of time constraints, and development of variables for in-
tervention, outcomes and covariates. Patients with a hospitalization for depression
and was discharged to home were selected. Additional inclusion criteria were a
minimum of one year of enrollment prior to and 60 days of enrollment following
discharge. Patient claims histories were searched to determine outpatient visits
with 7 and 30 days post-discharge and rehospitalization within 30 days post-dis-
charge. SAS procedures embedded in the tool were utilized for bivariate and mul-
tivariate analyses. RESULTS: The study included 39,985 patients. Patients with a
follow-up visit were slightly older and were more likely to be female. Prior to index
hospitalization, patients with follow-up were more likely to have filled an antide-
pressant or antianxiety medication and had a diagnosis of depression or anxiety
pre-index hospitalization. Little difference was found in the rate of pre-period
hospitalization. A logistic regression model found that having a follow-up visit
within 7 days of discharge was negatively and statistically significantly associated
with having a readmission within 30 days (odds ratio  0.88, CI0.80 – 0.97, once
other factors (demographics, diagnosis, and drug treatment) were controlled.
CONCLUSIONS: The data model and tool may be leveraged in a similar manner to
compare drug and medical treatment options more rapidly and efficiently.
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OBJECTIVES: Few studies of mental illness in Africa have centered on Alzheimer’s
disease. The primary aim of the study was to determine the prescribing patterns
and cost of drugs for Alzheimer’s disease in a South African private health care
sector patient population. METHODS: A retrospective drug utilization study was
conducted. Data were obtained from a South African private medical aid adminis-
trator for 2010. The database consisted of 2,126,264 records for medication and
procedures.RESULTS:A total of only 25 patients (13 females and 12 males) received
114 medicine items for Alzheimer’s disease at a cost of R70 794.11 (average cost per
item R621.00 (SDR208.73)). This medicine is relatively expensive, yet not all med-
ical aid schemes pay for medication for Alzheimer’s disease. The average age of
patients was 72.52 (SD10.03) years, with ages ranging from 46 to 88 years. Me-
mantine was the most frequently prescribed active ingredient (42.98% of prescrib-
ing frequency and 46.35% of cost), followed by donepezil (40.35% of frequency and
41.59% of cost). The average cost per memantine prescription was R669.61, fol-
lowed by R640.12 for donepezil and R449.35 for galantamine. The different medical
aids only paid, on average, 78.86% of the total amount claimed by patients for these
medicines. Most products were claimed between February and June 2010. Average
Prescribed Daily Doses (PDDs) of active ingredients were generally lower than their
respective Defined Daily Doses (DDDs). The average PDD for memantine was 18.27
mg (DDD20 mg), for donepezil was 7.07 mg (DDD7.5 mg) and for galantamine
was only 6.95 mg (DDD16 mg). Most prescriptions for memantine (75.51%) were
prescribed in its PDD of 20 mg. CONCLUSIONS: The results were generally similar
to those of previous South African studies. Studies on larger patient populations
are necessary to investigate the cost-effectiveness of the different treatment
options.
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OBJECTIVES: In short term clinical trials antipsychotic medications are well toler-
ated by children under six years old. While concerns have been raised about the
impact of long term exposure on metabolic and cardiovascular health and on the
developing brain, little is known about the extent of long term antipsychotic expo-
sure in this age group. This study quantifies antipsychotic exposure over a 4 year
period of children who began antipsychotic treatment before their sixth birthday
and identifies the variables associated with the risk of long term exposure.
METHODS: Children were identified who initiated an index episode of antipsy-
chotic treatment before their sixth birthday in Florida’s fee for service Medicaid
program. Using claims data the medication utilization of these children was
tracked during the year before and the four years following the start of their index
episodes (pre-index and four post-index periods). Generalized estimating equa-
tions were used to identify variables associated with the risk of additional days of
antipsychotic exposure. RESULTS: Five hundred twenty-eight children were in-
cluded in the cohort. The mean total days of exposure was 821.9 (431.9) repre-
senting 56.3 % of all days during the four post-index periods. The mean days of
exposure to combinations of antipsychotics and other classes of psychotherapeu-
tic medications were 623.8 447.6 days. Children with primary diagnoses of per-
vasive developmental disorders and affective disorders were at greater risk of ad-
ditional days of exposure than children with ADHD. Exposure tended to be greater
among children with indicators of clinical complexity including the presence of
secondary diagnoses and the use of other classes of psychotherapeutic medica-
tions in addition to antipsychotics. CONCLUSIONS: Exposure to antipsychotic me-
diations was extensive. Although these children may have had complex and severe
problems, additional research is urgently needed on the benefits and risks of long
term antipsychotic exposure among very young children.
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OBJECTIVES: Up to one-third of older adults fall each year with medications rep-
resenting a well-known risk factor for falling. Ultimately, falls that result in injury
are the true target of fall prevention and are of interest to healthcare practitioners.
Therefore, this meta-analysis focused on evaluating the association of antipsy-
chotic and antidepressant drugs with hip fracture, a common and debilitating
fall-related injury. METHODS: A search of Pubmed/Medline was conducted from
1966-2010 with key words including “antipsychotic agents”, “psychotropic drugs”,
“antidepressive agents”, “aged”, and “hip fracture”. Inclusion criteria included
mean age 65 years and statistical adjustment or stratification by age and gender.
Excluded were studies where hip fractures were not distinguished from other frac-
ture types or authors failed to answer queries for required information. A random
effects model was used to calculate summary odds ratios for the specific classes of
psychotropic medications. RESULTS: Of 166 studies identified, 10 antipsychotic-
related studies and 14 antidepressant-related studies met the inclusion criteria.
Combined, these studies represent over 70,000 hip fracture cases and approxi-
mately 272,000 total subjects from eight different nations and four continents.
Summary odds ratios include (95% confidence interval): conventional antipsychot-
ics 1.68 (1.43, 1.99), atypical antipsychotics 1.30 (1.14, 1.49), tricyclic anti-depres-
sants 1.71 (1.43, 2.04), and selective serotonin re-uptake inhibitors 1.94 (1.37, 2.76).
Although some studies reported drug-specific risk measures, the availability of
drug-specific data was limited. CONCLUSIONS: All classes considered in this anal-
ysis are associated with an increased risk of hip fracture in older adults. There is a
trend towards reduced risk associated with atypical antipsychotics compared to
conventional antipsychotics, although this does not reach statistical significance.
To minimize the risk of hip fracture in older adults requiring psychotropic medi-
cations, further research examining the association of hip fractures to specific
drugs within these classes is essential.
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OBJECTIVES: This post-hoc analysis assessed the risk and the factors associated
with relapse and hospitalizations during the 2-year treatment of outpatients
treated with oral olanzapine or olanzapine long-acting injection (LAI). METHODS:
We used data of a 104-week multicenter, effectiveness study comparing oral and
LAI olanzapine in the treatment of outpatients with schizophrenia (n524;
NCT00320489). Relapse was defined as hospitalization for schizophrenia; a 25%
increase from baseline on the PANSS total score (if baseline score 40), a 10 point
increase (if baseline score 40); a 1-point increase from baseline on the CGI-S
scale, provided that final CGI-S score was 4; deliberate self-injury or injury to
others that is associated with worsening of psychosis; or discontinuation from the
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